Leni van Doorn

1.7k total citations
56 papers, 1.2k citations indexed

About

Leni van Doorn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Leni van Doorn has authored 56 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Leni van Doorn's work include Gastric Cancer Management and Outcomes (12 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Leni van Doorn is often cited by papers focused on Gastric Cancer Management and Outcomes (12 papers), Cancer Treatment and Pharmacology (11 papers) and Colorectal Cancer Treatments and Studies (10 papers). Leni van Doorn collaborates with scholars based in Netherlands, United States and United Kingdom. Leni van Doorn's co-authors include Ferry A.L.M. Eskens, Jaap Verweij, Ron H.J. Mathijssen, Maja J.A. de Jonge, André Planting, F. Eskens, Sander Bins, Elisabeth G.E. de Vries, Jourik A. Gietema and Peter Stopfer and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

Leni van Doorn

54 papers receiving 1.2k citations

Peers

Countries citing papers authored by Leni van Doorn

Since Specialization

Citations

This map shows the geographic impact of Leni van Doorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leni van Doorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leni van Doorn more than expected).

Fields of papers citing papers by Leni van Doorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leni van Doorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leni van Doorn. The network helps show where Leni van Doorn may publish in the future.

Co-authorship network of co-authors of Leni van Doorn

This figure shows the co-authorship network connecting the top 25 collaborators of Leni van Doorn. A scholar is included among the top collaborators of Leni van Doorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leni van Doorn. Leni van Doorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine Learning–Based Prediction of Clinical Outcomes in Patients With Cancer Receiving Systemic Treatment Using Step Count Data Measured With Smartphones 2025 ·JCO Clinical Cancer Informatics ·(unknown), (unknown), Joeri A J Douma, Leni van Doorn, Evelien Kuip, Henk M.W. Verheul, Laurien M. Buffart	0
2	Effect of Switching the Histamine-1 Receptor Antagonist Clemastine to Cetirizine in Paclitaxel Premedication Regimens: The H1-Switch Study 2024 ·JCO Oncology Practice ·(unknown), Leni van Doorn, (unknown), (unknown), (unknown), Esther Oomen‐de Hoop, (unknown), Monique E.M.M. Bos, Birgit C. P. Koch, Roelof W. F. van Leeuwen	1
3	Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1 2023 ·Clinical Pharmacokinetics ·Mirjam de With, Leni van Doorn, (unknown), (unknown), Maja Matić, (unknown), Esther Oomen‐de Hoop, Esther van Meerten, Ron H. N. van Schaik, Ron H.J. Mathijssen, Sander Bins	7
4	Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD 2023 ·Biomedicine & Pharmacotherapy ·Mirjam de With, Leni van Doorn, (unknown), (unknown), Esther Oomen‐de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H. N. van Schaik, Sander Bins	13
5	Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases 2023 ·Biomedicine & Pharmacotherapy ·Nikki S. IJzerman, (unknown), Peter de Bruijn, Florian E. Buisman, Leni van Doorn, Pascal G. Doornebosch, (unknown), Cecile Grootscholten, Dirk J. Grünhagen, (unknown), Marjolein Y.V. Homs, Niels F. M. Kok, Cornelis Verhoef, Bas Groot Koerkamp, Koert F.D. Kuhlmann, Ron H.J. Mathijssen, Stijn L.W. Koolen	3
6	Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension 2022 ·British Journal of Cancer ·Leni van Doorn, (unknown), (unknown), Katrina M. Mirabito Colafella, Stijn L.W. Koolen, (unknown), Ingrid M. Garrelds, Dominique M. Bovée, Esther Oomen‐de Hoop, Sander Bins, Ferry A.L.M. Eskens, Ewout J. Hoorn, A.H. Jan Danser, Ron H.J. Mathijssen, Jorie Versmissen	7
7	Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma 2021 ·Pharmaceuticals ·Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L.W. Koolen, Teun van Gelder, Ron H.J. Mathijssen	8
8	The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients 2021 ·Pharmaceuticals ·Leni van Doorn, (unknown), Hánah N. Rier, Jeroen L.A. van Vugt, Charlotte van Kesteren, Sander Bins, Ron H.J. Mathijssen, Mark‐David Levin, Stijn L.W. Koolen	5
9	Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel 2021 ·Cancers ·Leni van Doorn, (unknown), Wendy M. van der Deure, Esther Oomen‐de Hoop, (unknown), (unknown), Ingrid Boere, (unknown), (unknown), Peter de Bruijn, Lena E. Friberg, Stijn L.W. Koolen, Ron H.J. Mathijssen, Agnes Jager	2
10	Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer 2021 ·Frontiers in Pharmacology ·Ruben A.G. van Eerden, Leni van Doorn, Femke M. de Man, (unknown), Michail Doukas, Thierry P. P. van den Bosch, Esther Oomen‐de Hoop, Peter de Bruijn, Sander Bins, (unknown), (unknown), Lena E. Friberg, Stijn L.W. Koolen, Manon C.W. Spaander, Ron H.J. Mathijssen	7
11	The added value of H2 antagonists in premedication regimens during paclitaxel treatment 2021 ·British Journal of Cancer ·(unknown), Leni van Doorn, (unknown), Esther Oomen‐de Hoop, Tessa M. Bosch, Patricia M. L. A. van den Bemt, Ingrid Boere, Agnes Jager, Ron H.J. Mathijssen, Roelof W. F. van Leeuwen	15
12	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib 2020 ·Pharmaceutics ·Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, (unknown), Eric D. Eisenmann, Alice A. Gibson, Esther Oomen‐de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L.W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H.J. Mathijssen, Alex Sparreboom, Sander Bins	10
13	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation 2015 ·Clinical Cancer Research ·Martijn P. Lolkema, Hilde Bohets, Hendrik‐Tobias Arkenau, Ann Lampo, Erio Barale-Thomas, Maja J.A. de Jonge, Leni van Doorn, Peter Hellemans, Johann S. de Bono, Ferry A.L.M. Eskens	68
14	A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies 2014 ·Clinical Colorectal Cancer ·Corina N.A.M. Oldenhuis, Walter J. Loos, Brooke Esteves, Leni van Doorn, Monette Cotreau, Andrew Strahs, (unknown), Jourik A. Gietema, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens	8
15	Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance 2013 ·Clinical Pharmacology & Therapeutics ·Jason A. Sprowl, Leni van Doorn, Shuiying Hu, L. Van Gerven, Peter de Bruijn, (unknown), Alice A. Gibson, Ron H.J. Mathijssen, Alex Sparreboom	65
16	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy 2012 ·Clinical Cancer Research ·Anne‐Joy M. de Graan, Walter J. Loos, Lena E. Friberg, Sharyn D. Baker, Jessica M. van der Bol, Leni van Doorn, Erik A.C. Wiemer, Bronno van der Holt, Jaap Verweij, Ron H.J. Mathijssen	29
17	A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors 2012 ·Clinical Cancer Research ·Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Kristeleit, Phillip Debnam, (unknown), Adam Stewart, Florence I. Raynaud, Michelle D. Garrett, Martin Toal, Leon Hooftman, Johann S. de Bono, Jaap Verweij, Ferry A.L.M. Eskens	64
18	Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors 2011 ·Clinical Cancer Research ·Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij	89
19	A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours 2007 ·British Journal of Cancer ·F. Eskens, Constantijne H. Mom, André Planting, Jourik A. Gietema, A. Amelsberg, Holger Huisman, Leni van Doorn, Henry Burger, Peter Stopfer, Jaap Verweij, Elisabeth G.E. de Vries	202
20	First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study 2007 ·British Journal of Cancer ·E. van Meerten, Ferry A.L.M. Eskens, (unknown), Leni van Doorn, Ate van der Gaast	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact